Yale Child Study Center

SciSparc Announces Initiation of Randomized Phase IIb Clinical Trial of its Proprietary SCI-110 for Tourette Syndrome

Retrieved on: 
Thursday, September 7, 2023
Yale Global Tic Severity Scale, Institutional review board, Yale School of Medicine, Federal Institute for Drugs and Medical Devices, Central nervous system, Medical device, Hannover Medical School, Yale Child Study Center, Spectrum, Clinical trial, Tourette syndrome, Federal Ministry of Health (Germany), Yale school, Disorder, TS, Ministry, TEL, Patient, Tel Aviv Sourasky Medical Center, Growth, Phase, Agitation, Safety, Pharmaceutical industry

TEL AVIV, Israel, Sept. 07, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, today announced the initiation of its Phase IIb Clinical Trial for its proprietary SCI-110 for the treatment of Tourette Syndrome (“TS”) at the Tel Aviv Sourasky Medical Center in Israel (“Sourasky”).

Key Points: 
  • The trial is based on the positive data results received from the single arm Yale School of Medicine study using SCI-110 for TS.
  • "The initiation of our Phase IIb Clinical Trial at Sourasky, the Israeli site, is a major milestone towards commercializing our proprietary SCI-110 for TS patients.
  • TS in adults can be a debilitating disorder for which current treatments result in limited benefits.
  • The patients will be randomized at a 1:1 ratio to receive either SCI-110 or a SCI-110-matched placebo.

Schools to Research the Impact of Their Environments On Students

Retrieved on: 
Wednesday, August 23, 2023
USC Rossier School of Education, Psychology, Learning, Yale University, University, Student, Yale Child Study Center, Teaching, Individual, Research, USC, Assistant, Chan Zuckerberg Initiative, School, New Village Girls Academy, Achievement Medal, Leonardo da Vinci, Growth, CZI, Safety, Nursing, Tutoring, Management, Education

REDWOOD CITY, Calif., Aug. 23, 2023 /PRNewswire/ -- Students today face a number of mental and emotional stressors both inside and outside of the classroom. While research has shown that student well-being is one of several critical conditions for learning that impact academic performance, most classrooms lack effective, research-backed tools to help educators understand the development of well-being in their students, in support of their academic success.

Key Points: 
  • This research is just one element of Project Flourish — a CZI supported effort to develop measurement tools that help K-12 schools and families better understand and support their students.
  • To date, through Project Flourish these tools have reached more than 3,500 students and helped educators better understand the academic and emotional needs of students across seven schools in New York City and Los Angeles.
  • These grants are part of CZI's Research to Practice portfolio which aims to support the implementation of promising research-backed tools in schools.
  • For more information about how CZI and our grant partners are supporting student and teacher well-being, visit chanzuckerberg.com/education/ .

SciSparc Receives Approval to Conduct Phase IIb Clinical Trial for SCI-110 to Treat Tourette Syndrome in Germany

Retrieved on: 
Friday, June 30, 2023
Yale Global Tic Severity Scale, Federal Institute for Drugs and Medical Devices, Central nervous system, Institutional review board, Medical device, Hannover Medical School, Yale School of Medicine, Yale Child Study Center, Clinical trial, Tourette syndrome, Federal Ministry of Health (Germany), Yale school, TS, TEL, Patient, Tel Aviv Sourasky Medical Center, Neurological disorder, Phase, Safety, Pharmaceutical industry

TEL AVIV, Israel, June 30, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced it has been granted an approval from the Federal Institute for Drugs and Medical Devices in Germany (“BfArM”) for its Phase IIb clinical trial to use SCI-110 for treating adults with Tourette Syndrome ("TS") at the Hannover Medical School in Hannover, Germany.

Key Points: 
  • The Company has already secured the Institutional Review Board (“IRB) approvals from all three clinical sites as well as the Israeli Ministry of Health's approval for the clinical trial at Sourasky.
  • "We are excited to announce that SciSparc has received another official approval to embark on its Phase IIb Clinical Trial for SCI-110, aimed at treating TS, in Germany.
  • This Phase IIb Clinical Trial will enable us to rigorously evaluate the safety and efficacy of SCI-110, and we believe will further solidify its potential as a game-changing therapy."
  • The patients will be randomized in a 1:1 ratio to receive either SCI-110 or a SCI-110-matched placebo.

NEW DATA FROM THE SCHOLASTIC KIDS & FAMILY READING REPORT™: 8TH EDITION STRENGTHENS EVIDENCE FOR POSITIVE CONNECTION BETWEEN MENTAL HEALTH OF KIDS AND LITERACY

Retrieved on: 
Tuesday, June 27, 2023
Linda, Partnership, Depression, Pediatrics, Kid, Education, Yale Child Study Center, Friends, Ipsos, Anxiety, Parent, Reading, Research, Grandparent, Multimedia, Doctor of Philosophy, Literacy, Magic: The Gathering core sets, 1993–2007, Arnold Gesell, Child, Fluency, Health, Mental health, Book, Psychology Today, Toy, Tutoring, Nursing, Scholastic, Psychology, MD, Child and adolescent psychiatry

To learn more about the Scholastic Kids & Family Reading Report, visit: www.scholastic.com/readingreport .

Key Points: 
  • To learn more about the Scholastic Kids & Family Reading Report, visit: www.scholastic.com/readingreport .
  • "To put it clearly, literacy is not just an educational intervention but is an investment in a child's health for the long-haul."
  • Our partnership with the Yale Child Study Center has strengthened our understanding of how literacy and mental wellness intersect.
  • The data from the new edition of the Kids & Family Reading Report show just how powerful the impact can be for children to support their discovery of engaging stories and lifelong reading habits."

SciSparc Announces IRB Approval to Conduct its Phase IIb Trial in Tourette Syndrome

Retrieved on: 
Wednesday, June 21, 2023
Yale Global Tic Severity Scale, Institutional review board, Central nervous system, Hannover Medical School, Tourette syndrome, TS, Yale School of Medicine, Yale Child Study Center, TEL, IRB, Tel Aviv Sourasky Medical Center, Yale University, Safety, Pharmaceutical industry, Medicine

TEL AVIV, Israel, June 21, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced it has received Institutional Review Board (IRB) approval for its Phase IIb clinical trial for SCI-110 in subjects suffering from Tourette Syndrome ("TS").

Key Points: 
  • TEL AVIV, Israel, June 21, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced it has received Institutional Review Board (IRB) approval for its Phase IIb clinical trial for SCI-110 in subjects suffering from Tourette Syndrome ("TS").
  • The objective of this Phase IIb randomized, multi-national, multi-center, double-blind, placebo controlled cross-over trial is to evaluate the efficacy, safety and tolerability of SciSparc's proprietary drug candidate SCI-110 in adults with TS (between 18 and 65 years of age).
  • Previously, SciSparc announced the Hannover Medical School in Hannover, Germany, and the Tel Aviv Sourasky Medical Center in Tel Aviv, Israel as medical center trial sites of excellence.
  • "We are excited to receive IRB approval for the trial from Yale University School of Medicine, which marks the achievement of another milestone towards the initiation of our Phase IIb clinical trial with TS subjects," stated SciSparc’s Chief Executive Officer, Oz Adler.

SciSparc Receives Final Approval to Commence its Phase IIb Clinical Trial for SCI-110 to treat Tourette Syndrome

Retrieved on: 
Tuesday, April 4, 2023
Yale University, Yale Global Tic Severity Scale, Yale School of Medicine, Central nervous system, Medical device, Hannover Medical School, Clinical trial, Tourette syndrome, Department of Neurology, Xuanwu hospital, TS, TEL, Patient, Tel Aviv Sourasky Medical Center, Trial, Psychiatry, Estonia, Yale Child Study Center, Safety, Pharmaceutical industry, Neurology

TEL AVIV, Israel, April 04, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced it has been granted final approval from the Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, required to commence the Company’s Phase IIb Clinical Trial for SCI-110 to treat Tourette Syndrome (“TS”).

Key Points: 
  • The Trial is titled “A randomized, double-blind, placebo controlled, cross-over study to evaluate the efficacy, safety and tolerability of daily oral SCI-110 in treating adults with Tourette Syndrome”.
  • The first clinical site to receive approval to initiate the trial is the Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, under the leadership of Prof. Tanya Gurevich, Head of Movement Disorders Unit, Department of Neurology.
  • “We are thrilled to launch our Phase IIb Clinical Trial in Israel and start enrollment of patients suffering from Tourette Syndrome.
  • "TS is estimated to affect 0.5-1% of the world's population, however the very few available treatments have limited efficacy and questionable safety.

SciSparc Receives Approval to conduct its Phase IIb Clinical Trial for SCI-110 to treat Tourette Syndrome

Retrieved on: 
Thursday, March 9, 2023
Yale Global Tic Severity Scale, TEL, Psychiatry, Tel Aviv Sourasky Medical Center, Clinical trial, Yale School of Medicine, Yale University, Estonia, Patient, Tourette syndrome, Yale Child Study Center, Hannover Medical School, Central nervous system, TS, Ministry, Department of Neurology, Xuanwu hospital, Ministry of Health (Israel), Medical device, Safety, Pharmaceutical industry, Neurology

TEL AVIV, Israel, March 09, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced the approval of the Israeli Ministry of Health to conduct its clinical trial titled “A randomized, double-blind, placebo controlled, cross-over study to evaluate the efficacy, safety and tolerability of daily oral SCI-110 in treating adults with Tourette Syndrome”.

Key Points: 
  • The first clinical site to receive approval to conduct the trial is Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, under the leadership of Prof. Tanya Gurevich, Head of Movement Disorders Unit, Department of Neurology.
  • “We are excited to be granted approval to conduct our Tourette Syndrome (“TS”) clinical trial in Israel.
  • This is another step for the Company's progress in the developments of much needed treatment for TS.
  • "TS is estimated to affect 0.5-1% of the world's population, however the very few available treatments have limited efficacy and questionable safety.

ANXIETY INSTITUTE ANNOUNCES SOLUTIONS-BASED COACHING PROGRAM FOR PARENTS OF CHILDREN WITH OCD AND ANXIETY

Retrieved on: 
Thursday, October 27, 2022
Linda, Anxiety, The Mars Generation, Behavior, Parent, OCD, Yale Child Study Center, Caregiver, Knowledge, CEO, Parenting, Program, Child, National, PSP, Tutoring, Pediatrics

GREENWICH, Conn. and MADISON, N.J., Oct. 27, 2022 /PRNewswire/ -- Anxiety Institute, a clinical research practice specializing in treating acute anxiety disorders in teenagers and young adults, announces a groundbreaking program for parents of anxious children.

Key Points: 
  • GREENWICH, Conn. and MADISON, N.J., Oct. 27, 2022 /PRNewswire/ -- Anxiety Institute, a clinical research practice specializing in treating acute anxiety disorders in teenagers and young adults, announces a groundbreaking program for parents of anxious children.
  • The Parent Strategy Program (PSP) is a coaching program designed for parents and caregivers to allow them to effectively and confidently parent a child who suffers from anxiety, OCD, or a related disorder.
  • Over ten personalized on-line interactive sessions, follow-ups and check-ins, parents receive step-by-step strategies to manage their children's anxiety related behaviors.
  • A parent graduate of the program agrees "The Parent Strategy Program at Anxiety Institute was terrific.

Free Webinar: Helping Parents Discern When to Worry About Their Teen

Retrieved on: 
Monday, September 26, 2022
Pressure, Adult, American Psychological Association, University, Education, Aspen Education Group, Yale University, Stress, Senior advisor, UNICEF, Pandemic, FEG, News, Face, Private practice, Clinical psychology, University of Michigan School of Information, CBS News, Book, Mental health, Fellow, Epidemic, District, Adolescence, Student, Yale Child Study Center, Fusion Academy, Leadership, Buffalo Public Schools, School, Research, Parent, Social policy, Multimedia, Case Western Reserve University, Barnstable Academy, Medicine, Toy, Birth control, Tutoring, Child, The New York Times, Anxiety

GRAND RAPIDS, Mich., Sept. 26, 2022 /PRNewswire/ -- Dr. Lisa Damour, Ph.D. will guide parents through the emotional roller coaster of the middle and high school years during a live virtual webinar Wednesday hosted by Fusion Education Group.

Key Points: 
  • Dr. Damour will also reassure parents that many of the emotional and mental health challenges teens currently face existed before March of 2020.
  • Parents don't always know how to tell if they are looking at a passing mood, or real grounds for concern.
  • We'll delve into when and when not to worry and detail the most important ways that parents can support teens."
  • She and her husband are the proud parents of two daughters.

SciSparc Signs Clinical Trial Agreement with Yale University to Conduct its Phase IIb Trial in Tourette Syndrome

Retrieved on: 
Monday, August 1, 2022
Patient, Hannover Medical School, CBD, Yale Global Tic Severity Scale, Yale Child Study Center, GLOBE, Learning, U.S. Securities and Exchange Commission, THC, SEC, Tel Aviv Sourasky Medical Center, Research, Risk, EMA, Tourette syndrome, Alzheimer's disease, Private Securities Litigation Reform Act, Intention, Status epilepticus, Adult, Safety, Movement, Agitation, Clinical trial, Central nervous system, TS, FDA, Company, Nasdaq, Chief technology officer, Pain, Autism, Phase, Annual report, Yale University, European Medicines Agency, Tic, Population, TEL, Pharmaceutical industry, Medical device, U.S

TEL AVIV, Israel, Aug. 01, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced the addition of another site of excellence, the Yale Child Study Center at Yale University, to its Phase IIb clinical trial for SCI-110 in patients suffering from Tourette Syndrome ("TS").

Key Points: 
  • Yale University is the third medical center to join SciSparcs multi-national, multi-center trial.
  • We are very excited about the opportunity to return and collaborate with Dr. Bloch and his team at Yale University.
  • Previously, a Phase IIa trial, conducted at the same site at Yale University, showed that trial patients, which were TS medication-refractory, had a reduction of tic symptoms of 21% across the entire sample.
  • Based on these positive results, the Company is currently advancing into a Phase IIb trial.